1. Medtech Insight

Market Intel: How Augmented, Mixed And Virtual Reality Tech Unveils New Possibilities For Surgeons

 
• By Marion Webb

Immersive technologies are becoming a reality in the OR. The second part of Medtech Insight’s series on the “Future of Surgery” introduces innovators of VR simulation tech, AR surgery platforms and AR Smart Glasses, and provides insights from world-renowned AR surgeons.    

ARsurgery

In the post-pandemic world, health care professionals and surgeons will increasingly turn to immersive technologies – augmented reality (AR), virtual reality (VR) and mixed reality (MR) – which open up new possibilities for learning, remote collaboration, enhanced performance and collecting data.

AR, which enhances the real world with digital twins, allows surgeons to overlay data and visuals over a patient’s body...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.